| pubmed-article:10023661 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0014597 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C1704256 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0021853 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C1510411 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0387583 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0214897 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:10023661 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:10023661 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10023661 | pubmed:dateCreated | 1999-2-23 | lld:pubmed |
| pubmed-article:10023661 | pubmed:abstractText | The precise role of TGF-beta in colorectal carcinogenesis is not clear. The purpose of this study was to determine the phenotypic alterations caused by chronic exposure to TGF-beta in non-transformed intestinal epithelial (RIE-1) cells. Growth of RIE-1 cells was inhibited by >75% following TGF-beta1 treatment for 7 days, after which the cells resumed a normal growth despite the presence of TGF-beta1. These 'TGF-beta-resistant' cells (RIE-Tr) were continuously exposed to TGF-beta for >50 days. Unlike the parental RIE cells, RIE-Tr cells lost contact inhibition, formed foci in culture, grew in soft agarose. RIE-Tr cells demonstrated TGF-beta-dependent invasive potential in an in vitro assay and were resistant to Matrigel and Na-butyrate-induced apoptosis. The RIE-Tr cells were also tumorigenic in nude mice. The transformed phenotype of RIE-Tr cells was associated with a 95% decrease in the level of the type II TGF-beta receptor (TbetaRII) protein, a 40-fold increase in cyclooxygenase-2 (COX-2) protein, and 5.9-fold increase in the production of prostacyclin. Most RIE-Tr subclones that expressed low levels of TbetaRII and high levels of COX-2 were tumorigenic. Those subclones that express abundant TbetaRII and low levels of COX-2 were not tumorigenic in nude mice. A selective COX-2 inhibitor inhibited RIE-Tr cell growth in culture and tumor growth in nude mice. The reduced expression of TbetaRII, increased expression of COX-2, and the ability to form colonies in Matrigel were all reversible upon withdrawal of exogenous TGF-beta1 for the RIE-Tr cells. | lld:pubmed |
| pubmed-article:10023661 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10023661 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10023661 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10023661 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10023661 | pubmed:issn | 0950-9232 | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:ShawBB | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:IsaksonP CPC | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:AlboDD | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:BeauchampR... | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:ShengHH | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:BergerD HDH | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:DuBoisR NRN | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:LamplCC | lld:pubmed |
| pubmed-article:10023661 | pubmed:author | pubmed-author:O'MahonyC ACA | lld:pubmed |
| pubmed-article:10023661 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10023661 | pubmed:day | 28 | lld:pubmed |
| pubmed-article:10023661 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:10023661 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10023661 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10023661 | pubmed:pagination | 855-67 | lld:pubmed |
| pubmed-article:10023661 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:meshHeading | pubmed-meshheading:10023661... | lld:pubmed |
| pubmed-article:10023661 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10023661 | pubmed:articleTitle | Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. | lld:pubmed |
| pubmed-article:10023661 | pubmed:affiliation | Department of Surgery, The Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. | lld:pubmed |
| pubmed-article:10023661 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10023661 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10023661 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10023661 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10023661 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10023661 | lld:pubmed |
